Thumbnail Image
Publication

Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy

Oing, C.
; 
Bristow, Robert G
Citations
Altmetric:
Abstract
Authors
Oing, C.
Bristow, Robert G
Affiliation
Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
Description
Date
2023
Publisher
Collections
All Paterson Institute for Cancer Research
Show all metadata
Files
Thumbnail Image
Identified with Open Access button
Adobe PDF, 242.48 KB
Keywords
Type
Other
Citation
Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO open. 2023 Mar 20;8(2):101194. PubMed PMID: 36947986. Pubmed Central PMCID: PMC10040503 Pharmaceuticals; speaker’s honoraria and/or advisory board participation: AstraZeneca, Ipsen, Roche, Sandoz; research funding: PharmaMar (non-financial), all outside the submitted work. RGB has declared no conflicts of interest. Epub 2023/03/23. eng.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626172
Embedded videos